Biogen to collaborate with NeuroSense on ALS trial

14 June 2023

Israel-based NeuroSense Therapeutics (Nasdaq: NRSN) announced in a Securities and Exchange Commission that it has entered into a collaborative evaluation agreement with a unit of US biotech major Biogen (Nasdaq: BIIB). NeuroSense share gained more than 6% to $1.90 in pre-market trading on the new.

The deal will see Biogen evaluate the impact of PrimeC on neurofilament levels in the plasma of participants in PARADIGM, NeuroSense’s Phase IIb clinical trial for the treatment of amyotrophic lateral sclerosis (ALS). Biogen will fund the neurofilament biomarker study and conduct the analysis.

Biogen recently has its own success in the ALS space, gaining US regulatory approval for its Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK